A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction‐associated steatotic liver disease
Abstract Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a systemic disease with insulin resistance at its core. It affects one‐third of the world population. Fibroblast growth factor (FGF21)‐based therapies are effective in lowering hepatic fat content and fibrosis re...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|